Taken together, this highlights the importance of ARMH1 as EZH2 interactant at the post-translational level and provides insights into its involvement in high-risk factors and therapeutic resistance mechanisms, in pediatric AML. This evidence concerns the gene ARMH1 and acute myeloid leukemia.